Factors Associated with Age Disparities among Cancer Clinical Trial Participants

Ethan B. Ludmir, Walker Mainwaring, Timothy A. Lin, Austin B. Miller, Amit Jethanandani, Andres F. Espinoza, Jacob J. Mandel, Steven H. Lin, Benjamin D. Smith, Grace L. Smith, Noam A. Vanderwalde, Bruce D. Minsky, Albert C. Koong, Thomas E. Stinchcombe, Reshma Jagsi, Daniel R. Gomez, Charles Thomas, C. David Fuller

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Importance: Seminal investigation 2 decades ago alerted the oncology community to age disparities in participation in cooperative group trials; less is known about whether these disparities persist in industry-funded research. Objective: To characterize the age disparities among trial enrollees on randomized clinical trials (RCTs) of common cancers in clinical oncology and identify factors associated with wider age imbalances. Data Sources: Phase 3 clinical oncology RCTs were identified through ClinicalTrials.gov. Study Selection: Multiarm RCTs assessing a therapeutic intervention for patients with breast, prostate, colorectal, or lung cancer (the 4 most common cancer disease sites) were included. Data Extraction and Synthesis: Trial data were extracted from ClinicalTrials.gov. Trial screening and parameter identification were independently performed by 2 individuals. Data were analyzed in 2018. Main Outcomes and Measures: The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was determined for each trial. Results: Three hundred two trials met inclusion criteria. Thr trails collectively enrolled 262354 participants; 249 trials (82.5%) were industry-funded. For all trials, the trial median age of trial participants was a mean of 6.49 years younger than the population median age (95% CI, -7.17 to -5.81 years; P <.001). Age disparities were heightened among industry-funded trials compared with non-industry-funded trials (mean DMA, -6.84 vs -4.72 years; P =.002). Enrollment criteria restrictions based on performance status or age cutoffs were associated with age disparities; however, industry-funded trials were not more likely to use these enrollment restrictions than non-industry-funded trials. Age disparities were also larger among trials that evaluated a targeted systemic therapy and among lung cancer trials. Linear regression modeling revealed a widening gap between trial and population median ages over time at a rate of -0.19 years annually (95% CI, -0.37 to -0.01 years; P =.04). Conclusions and Relevance: Age disparities between trial participants and the incident disease population are pervasive across trials and appear to be increasing over time. Industry sponsorship of trials is associated with heightened age imbalances among trial participants. With an increasing role of industry funding among cancer trials, efforts to understand and address age disparities are necessary to ensure generalizability of trial results as well as equity in trial access..

Original languageEnglish (US)
JournalJAMA Oncology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Industry
Clinical Trials
Neoplasms
Medical Oncology
Randomized Controlled Trials
Population
Lung Neoplasms
Information Storage and Retrieval
Colorectal Neoplasms
Linear Models
Prostatic Neoplasms
Breast
Outcome Assessment (Health Care)
Therapeutics
Research

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ludmir, E. B., Mainwaring, W., Lin, T. A., Miller, A. B., Jethanandani, A., Espinoza, A. F., ... Fuller, C. D. (2019). Factors Associated with Age Disparities among Cancer Clinical Trial Participants. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2019.2055

Factors Associated with Age Disparities among Cancer Clinical Trial Participants. / Ludmir, Ethan B.; Mainwaring, Walker; Lin, Timothy A.; Miller, Austin B.; Jethanandani, Amit; Espinoza, Andres F.; Mandel, Jacob J.; Lin, Steven H.; Smith, Benjamin D.; Smith, Grace L.; Vanderwalde, Noam A.; Minsky, Bruce D.; Koong, Albert C.; Stinchcombe, Thomas E.; Jagsi, Reshma; Gomez, Daniel R.; Thomas, Charles; Fuller, C. David.

In: JAMA Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Ludmir, EB, Mainwaring, W, Lin, TA, Miller, AB, Jethanandani, A, Espinoza, AF, Mandel, JJ, Lin, SH, Smith, BD, Smith, GL, Vanderwalde, NA, Minsky, BD, Koong, AC, Stinchcombe, TE, Jagsi, R, Gomez, DR, Thomas, C & Fuller, CD 2019, 'Factors Associated with Age Disparities among Cancer Clinical Trial Participants', JAMA Oncology. https://doi.org/10.1001/jamaoncol.2019.2055
Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF et al. Factors Associated with Age Disparities among Cancer Clinical Trial Participants. JAMA Oncology. 2019 Jan 1. https://doi.org/10.1001/jamaoncol.2019.2055
Ludmir, Ethan B. ; Mainwaring, Walker ; Lin, Timothy A. ; Miller, Austin B. ; Jethanandani, Amit ; Espinoza, Andres F. ; Mandel, Jacob J. ; Lin, Steven H. ; Smith, Benjamin D. ; Smith, Grace L. ; Vanderwalde, Noam A. ; Minsky, Bruce D. ; Koong, Albert C. ; Stinchcombe, Thomas E. ; Jagsi, Reshma ; Gomez, Daniel R. ; Thomas, Charles ; Fuller, C. David. / Factors Associated with Age Disparities among Cancer Clinical Trial Participants. In: JAMA Oncology. 2019.
@article{5ce65c454f854cb8bac73a99d686f3c3,
title = "Factors Associated with Age Disparities among Cancer Clinical Trial Participants",
abstract = "Importance: Seminal investigation 2 decades ago alerted the oncology community to age disparities in participation in cooperative group trials; less is known about whether these disparities persist in industry-funded research. Objective: To characterize the age disparities among trial enrollees on randomized clinical trials (RCTs) of common cancers in clinical oncology and identify factors associated with wider age imbalances. Data Sources: Phase 3 clinical oncology RCTs were identified through ClinicalTrials.gov. Study Selection: Multiarm RCTs assessing a therapeutic intervention for patients with breast, prostate, colorectal, or lung cancer (the 4 most common cancer disease sites) were included. Data Extraction and Synthesis: Trial data were extracted from ClinicalTrials.gov. Trial screening and parameter identification were independently performed by 2 individuals. Data were analyzed in 2018. Main Outcomes and Measures: The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was determined for each trial. Results: Three hundred two trials met inclusion criteria. Thr trails collectively enrolled 262354 participants; 249 trials (82.5{\%}) were industry-funded. For all trials, the trial median age of trial participants was a mean of 6.49 years younger than the population median age (95{\%} CI, -7.17 to -5.81 years; P <.001). Age disparities were heightened among industry-funded trials compared with non-industry-funded trials (mean DMA, -6.84 vs -4.72 years; P =.002). Enrollment criteria restrictions based on performance status or age cutoffs were associated with age disparities; however, industry-funded trials were not more likely to use these enrollment restrictions than non-industry-funded trials. Age disparities were also larger among trials that evaluated a targeted systemic therapy and among lung cancer trials. Linear regression modeling revealed a widening gap between trial and population median ages over time at a rate of -0.19 years annually (95{\%} CI, -0.37 to -0.01 years; P =.04). Conclusions and Relevance: Age disparities between trial participants and the incident disease population are pervasive across trials and appear to be increasing over time. Industry sponsorship of trials is associated with heightened age imbalances among trial participants. With an increasing role of industry funding among cancer trials, efforts to understand and address age disparities are necessary to ensure generalizability of trial results as well as equity in trial access..",
author = "Ludmir, {Ethan B.} and Walker Mainwaring and Lin, {Timothy A.} and Miller, {Austin B.} and Amit Jethanandani and Espinoza, {Andres F.} and Mandel, {Jacob J.} and Lin, {Steven H.} and Smith, {Benjamin D.} and Smith, {Grace L.} and Vanderwalde, {Noam A.} and Minsky, {Bruce D.} and Koong, {Albert C.} and Stinchcombe, {Thomas E.} and Reshma Jagsi and Gomez, {Daniel R.} and Charles Thomas and Fuller, {C. David}",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamaoncol.2019.2055",
language = "English (US)",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Factors Associated with Age Disparities among Cancer Clinical Trial Participants

AU - Ludmir, Ethan B.

AU - Mainwaring, Walker

AU - Lin, Timothy A.

AU - Miller, Austin B.

AU - Jethanandani, Amit

AU - Espinoza, Andres F.

AU - Mandel, Jacob J.

AU - Lin, Steven H.

AU - Smith, Benjamin D.

AU - Smith, Grace L.

AU - Vanderwalde, Noam A.

AU - Minsky, Bruce D.

AU - Koong, Albert C.

AU - Stinchcombe, Thomas E.

AU - Jagsi, Reshma

AU - Gomez, Daniel R.

AU - Thomas, Charles

AU - Fuller, C. David

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Importance: Seminal investigation 2 decades ago alerted the oncology community to age disparities in participation in cooperative group trials; less is known about whether these disparities persist in industry-funded research. Objective: To characterize the age disparities among trial enrollees on randomized clinical trials (RCTs) of common cancers in clinical oncology and identify factors associated with wider age imbalances. Data Sources: Phase 3 clinical oncology RCTs were identified through ClinicalTrials.gov. Study Selection: Multiarm RCTs assessing a therapeutic intervention for patients with breast, prostate, colorectal, or lung cancer (the 4 most common cancer disease sites) were included. Data Extraction and Synthesis: Trial data were extracted from ClinicalTrials.gov. Trial screening and parameter identification were independently performed by 2 individuals. Data were analyzed in 2018. Main Outcomes and Measures: The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was determined for each trial. Results: Three hundred two trials met inclusion criteria. Thr trails collectively enrolled 262354 participants; 249 trials (82.5%) were industry-funded. For all trials, the trial median age of trial participants was a mean of 6.49 years younger than the population median age (95% CI, -7.17 to -5.81 years; P <.001). Age disparities were heightened among industry-funded trials compared with non-industry-funded trials (mean DMA, -6.84 vs -4.72 years; P =.002). Enrollment criteria restrictions based on performance status or age cutoffs were associated with age disparities; however, industry-funded trials were not more likely to use these enrollment restrictions than non-industry-funded trials. Age disparities were also larger among trials that evaluated a targeted systemic therapy and among lung cancer trials. Linear regression modeling revealed a widening gap between trial and population median ages over time at a rate of -0.19 years annually (95% CI, -0.37 to -0.01 years; P =.04). Conclusions and Relevance: Age disparities between trial participants and the incident disease population are pervasive across trials and appear to be increasing over time. Industry sponsorship of trials is associated with heightened age imbalances among trial participants. With an increasing role of industry funding among cancer trials, efforts to understand and address age disparities are necessary to ensure generalizability of trial results as well as equity in trial access..

AB - Importance: Seminal investigation 2 decades ago alerted the oncology community to age disparities in participation in cooperative group trials; less is known about whether these disparities persist in industry-funded research. Objective: To characterize the age disparities among trial enrollees on randomized clinical trials (RCTs) of common cancers in clinical oncology and identify factors associated with wider age imbalances. Data Sources: Phase 3 clinical oncology RCTs were identified through ClinicalTrials.gov. Study Selection: Multiarm RCTs assessing a therapeutic intervention for patients with breast, prostate, colorectal, or lung cancer (the 4 most common cancer disease sites) were included. Data Extraction and Synthesis: Trial data were extracted from ClinicalTrials.gov. Trial screening and parameter identification were independently performed by 2 individuals. Data were analyzed in 2018. Main Outcomes and Measures: The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was determined for each trial. Results: Three hundred two trials met inclusion criteria. Thr trails collectively enrolled 262354 participants; 249 trials (82.5%) were industry-funded. For all trials, the trial median age of trial participants was a mean of 6.49 years younger than the population median age (95% CI, -7.17 to -5.81 years; P <.001). Age disparities were heightened among industry-funded trials compared with non-industry-funded trials (mean DMA, -6.84 vs -4.72 years; P =.002). Enrollment criteria restrictions based on performance status or age cutoffs were associated with age disparities; however, industry-funded trials were not more likely to use these enrollment restrictions than non-industry-funded trials. Age disparities were also larger among trials that evaluated a targeted systemic therapy and among lung cancer trials. Linear regression modeling revealed a widening gap between trial and population median ages over time at a rate of -0.19 years annually (95% CI, -0.37 to -0.01 years; P =.04). Conclusions and Relevance: Age disparities between trial participants and the incident disease population are pervasive across trials and appear to be increasing over time. Industry sponsorship of trials is associated with heightened age imbalances among trial participants. With an increasing role of industry funding among cancer trials, efforts to understand and address age disparities are necessary to ensure generalizability of trial results as well as equity in trial access..

UR - http://www.scopus.com/inward/record.url?scp=85066498166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066498166&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.2055

DO - 10.1001/jamaoncol.2019.2055

M3 - Article

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

ER -